Evoke Pharma Inc. [NASDAQ: EVOK] stock went on a downward path that fall over -20.97% on Friday, amounting to a one-week price decrease of less than -8.24%. The company report on March 12, 2021 that Evoke Pharma Reports Fourth Quarter and Full Year 2020 Financial Results.
Encouraging early traction from GIMOTI™ commercial launch.
Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases, announced its financial results for the fourth quarter ended December 31, 2020 and recent corporate developments.
Over the last 12 months, EVOK stock rose by 169.23%. The average equity rating for EVOK stock is currently 2.00, trading closer to a bullish pattern in the stock market.
The market cap for the stock reached $97.09 million, with 26.39 million shares outstanding and 22.43 million shares in the current float. Compared to the average trading volume of 659.28K shares, EVOK stock reached a trading volume of 3652888 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Guru’s Opinion on Evoke Pharma Inc. [EVOK]:
H.C. Wainwright have made an estimate for Evoke Pharma Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on June 22, 2020. The new note on the price target was released on March 05, 2019, representing the official price target for Evoke Pharma Inc. stock. Previously, the target price had yet another drop from $10 to $5, while B. Riley FBR Inc. kept a Buy rating on EVOK stock.
The Average True Range (ATR) for Evoke Pharma Inc. is set at 0.35
EVOK Stock Performance Analysis:
Evoke Pharma Inc. [EVOK] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -8.24. With this latest performance, EVOK shares dropped by -35.86% in over the last four-week period, additionally sinking by -51.58% over the last 6 months – not to mention a rise of 169.23% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for EVOK stock in for the last two-week period is set at 38.65, with the RSI for the last a single of trading hit 34.05, and the three-weeks RSI is set at 41.45 for Evoke Pharma Inc. [EVOK]. The present Moving Average for the last 50 days of trading for this stock 2.95, while it was recorded at 2.82 for the last single week of trading, and 3.61 for the last 200 days.
Insight into Evoke Pharma Inc. Fundamentals:
Operating Margin for any stock indicates how profitable investing would be, and Evoke Pharma Inc. [EVOK] shares currently have an operating margin of -56678.32 and a Gross Margin at -276.68. Evoke Pharma Inc.’s Net Margin is presently recorded at -57144.53.
Return on Total Capital for EVOK is now -398.37, given the latest momentum, and Return on Invested Capital for the company is -426.69. Return on Equity for this stock declined to -2,256.53, with Return on Assets sitting at -166.20. Additionally, EVOK Total Debt to Total Capital is recorded at 258.26, with Total Debt to Total Assets ending up at 55.61.
Reflecting on the efficiency of the workforce at the company, Evoke Pharma Inc. [EVOK] managed to generate an average of -$2,630,934 per employee. Receivables Turnover for the company is 1.98 with a Total Asset Turnover recorded at a value of 0.00.Evoke Pharma Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.20 and a Current Ratio set at 1.20.
EVOK Stock EPS
With the latest financial reports released by the company, Evoke Pharma Inc. posted -0.07/share EPS, while the average EPS was predicted by analysts to be reported at -0.05/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -40.00%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for EVOK. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Evoke Pharma Inc. go to 40.00%.
Evoke Pharma Inc. [EVOK] Insider Position Details
There are presently around $6 million, or 15.00% of EVOK stock, in the hands of institutional investors. The top three institutional holders of EVOK stocks are: VANGUARD GROUP INC with ownership of 1,030,084, which is approximately -0.35% of the company’s market cap and around 2.00% of the total institutional ownership; MORGAN STANLEY, holding 504,013 shares of the stock with an approximate value of $1.24 million in EVOK stocks shares; and RENAISSANCE TECHNOLOGIES LLC, currently with $0.46 million in EVOK stock with ownership of nearly 739.803% of the company’s market capitalization.
Positions in Evoke Pharma Inc. stocks held by institutional investors increased at the end of March and at the time of the March reporting period, where 17 institutional holders increased their position in Evoke Pharma Inc. [NASDAQ:EVOK] by around 798,177 shares. Additionally, 8 investors decreased positions by around 45,261 shares, while 9 investors held positions by with 1,772,461 shares. The mentioned changes placed institutional holdings at 2,615,899 shares, according to the latest SEC report filing. EVOK stock had 7 new institutional investments in for a total of 94,853 shares, while 3 institutional investors sold positions of 24,547 shares during the same period.